Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
Latest Information Update: 11 Mar 2024
Price :
$35 *
At a glance
- Drugs Lasmiditan (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms CENTURION
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
- 24 Mar 2023 Results from the open-label extension of the CENTURION randomized trial published in the Cephalalgia
- 10 Dec 2022 Results from the open label extension evaluating dose optimization, patterns of use, migraine-related disability, and quality of life during lasmiditan treatment, presented at the 16th European headache federation COngress
- 17 Sep 2022 Results (n=208) of post hoc analysis of randomized controlled phase 3 CENTURION Trial assessing the safety profile of lasmiditan in the Chinese population published in the Advances in Therapy